Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bio Plus Co., Ltd (099430.KQ)
Seongnam-si, US
Based in Seongnam-si, South Korea, Bio Plus Co., Ltd, established in 2003, is dedicated to the investigation, formulation, production, and commercialization of bio-based items. The company’s diverse offerings include a variety of dermal fillers, such as SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses. Additionally, Bio Plus manufactures critical medical products: InterBlock, an absorbable anti-adhesion barrier; Synofil, utilized for synovial fluid replacement; and Blad-Care, a treatment for temporary alleviation of cystitis discomfort. Its mesotherapy portfolio features Kiara Reju for skin revitalization, Slim Slimmer for lipolysis, LumiDew for skin brightening, and JuveniHill for addressing wrinkles. The firm also supplies hair and scalp wellness products under the BelloHa and BellaChe names. Rounding out its extensive catalog are La Bella brand cosmetics, which include heparinoid essence, EGF balls, and specialized skin care gels.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.81% | -9.89% | -3.81% | +9.23% | -3.81% | +8.59% | -20.11% | -13.66% | -31.46% | -31.46% | -31.46% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+36.9% ★ Q1'26: +15.4% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-39.7% Q1'26: -15.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-8.1% Q1'26: +9.8% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+16.5% ★ Q1'26: +27.5% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+6.6% ★ Q1'26: +12.6% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+78.0% Q1'26: +2.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×4.00× Q1'26: 1.88× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
65.04B
est: 71.60B (-9.2%)
|
66.41B
est: 61.66B (+7.7%)
|
90.90B
est: 102.30B (-11.1%)
|
120.60B
120.60B – 120.60B
+17.9% YoY
|
140.80B
140.80B – 140.80B
+16.7% YoY
|
| EBITDA |
30.52B
est: 33.54B (-9.0%)
|
21.20B
est: 24.17B (-12.3%)
|
15.01B
est: 40.10B (-62.6%)
|
47.27B
47.27B – 47.27B
+17.9% YoY
|
55.19B
55.19B – 55.19B
+16.7% YoY
|
| EBIT |
28.03B
est: 30.72B (-8.8%)
|
17.93B
est: 22.25B (-19.4%)
|
15.01B
est: 36.92B (-59.4%)
|
43.52B
43.52B – 43.52B
+17.9% YoY
|
50.81B
50.81B – 50.81B
+16.7% YoY
|
| Net Income |
25.58B
est: 23.07B (+10.9%)
|
14.15B
est: 35.34B (-60.0%)
|
15.00B
est: 48.63B (-69.2%)
|
60.21B
60.21B – 60.21B
+23.8% YoY
|
65.44B
65.44B – 65.44B
+8.7% YoY
|
| SGA |
3.23B
est: 4.09B (-21.0%)
|
6.59B
est: 9.23B (-28.6%)
|
45.60B
est: 15.32B (+197.7%)
|
18.06B
18.06B – 18.06B
+17.9% YoY
|
21.08B
21.08B – 21.08B
+16.7% YoY
|
| EPS |
445.00
est: 408.00 (+9.1%)
|
250.22
est: 351.00 (-28.7%)
|
253.00
est: 483.00 (-47.6%)
|
598.00
598.00 – 598.00
+23.8% YoY
|
650.00
650.00 – 650.00
+8.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-15 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-14 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hyun-Kyu Jung | Chief Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 099430.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
